October 29, 2021
1 min read

Curacle, Théa reach rights agreement for potential first oral therapy for wet AMD and DME

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Curacle and Théa Open Innovation have entered an agreement for the development of the potential first oral treatment for diabetic macular edema, according to a press release.

The treatment, CU06-RE, may also be used to treat wet age-related macular degeneration.

“Through this licensing collaboration, Théa and Curacle will provide a new first-in-class treatment with an alternative and non-invasive route of administration and most importantly, convenience for patients,” Théa president Jean-Frédéric Chibret said in the release.

Curacle will receive $6 million up front and is eligible to receive an additional $157.5 million in development, regulatory and sales milestones. If the treatment is successfully developed, Curacle will also be eligible for sales royalties. Both companies will collaborate on CU06-RE’s clinical development, with Curacle initiating phase 1 and 2 clinical trials and Théa offering infrastructural and financial support.

Curacle will retain marketing rights in all countries in Asia, while Théa will gain marketing rights for the rest of the world.